A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Celltrion
- 13 Feb 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 This trial has been completed in Bulgarian drug agency.
- 06 Feb 2019 This trial has been completed in Greece.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History